Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.

Nistala H, Lee-Arteaga S, Carta L, Cook JR, Smaldone S, Siciliano G, Rifkin AN, Dietz HC, Rifkin DB, Ramirez F.

Hum Mol Genet. 2010 Dec 15;19(24):4790-8. doi: 10.1093/hmg/ddq409. Epub 2010 Sep 24. Erratum in: Hum Mol Genet. 2014 Nov 15;23(22):6137.

2.

Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation.

Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Carta L, Ono RN, Sengle G, Arteaga-Solis E, Levasseur R, Ducy P, Sakai LY, Karsenty G, Ramirez F.

J Cell Biol. 2010 Sep 20;190(6):1107-21. doi: 10.1083/jcb.201003089.

3.

Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGF{beta} stimulation of RANKL production.

Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Ramirez F.

J Biol Chem. 2010 Oct 29;285(44):34126-33. doi: 10.1074/jbc.M110.125328. Epub 2010 Aug 21.

4.

Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling.

Craft CS, Zou W, Watkins M, Grimston S, Brodt MD, Broekelmann TJ, Weinbaum JS, Teitelbaum SL, Pierce RA, Civitelli R, Silva MJ, Mecham RP.

J Biol Chem. 2010 Jul 30;285(31):23858-67. doi: 10.1074/jbc.M110.113019. Epub 2010 May 25.

5.

Osteopontin deficiency increases bone fragility but preserves bone mass.

Thurner PJ, Chen CG, Ionova-Martin S, Sun L, Harman A, Porter A, Ager JW 3rd, Ritchie RO, Alliston T.

Bone. 2010 Jun;46(6):1564-73. doi: 10.1016/j.bone.2010.02.014. Epub 2010 Feb 18.

6.

Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling.

Ramirez F, Rifkin DB.

Curr Opin Cell Biol. 2009 Oct;21(5):616-22. doi: 10.1016/j.ceb.2009.05.005. Epub 2009 Jun 12. Review.

7.

Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions.

Yakar S, Canalis E, Sun H, Mejia W, Kawashima Y, Nasser P, Courtland HW, Williams V, Bouxsein M, Rosen C, Jepsen KJ.

J Bone Miner Res. 2009 Aug;24(8):1481-92. doi: 10.1359/jbmr.090226.

8.

Phenotypic integration of skeletal traits during growth buffers genetic variants affecting the slenderness of femora in inbred mouse strains.

Jepsen KJ, Hu B, Tommasini SM, Courtland HW, Price C, Cordova M, Nadeau JH.

Mamm Genome. 2009 Jan;20(1):21-33. doi: 10.1007/s00335-008-9158-1. Epub 2008 Dec 5.

9.

Decorin modulates collagen matrix assembly and mineralization.

Mochida Y, Parisuthiman D, Pornprasertsuk-Damrongsri S, Atsawasuwan P, Sricholpech M, Boskey AL, Yamauchi M.

Matrix Biol. 2009 Jan;28(1):44-52. doi: 10.1016/j.matbio.2008.11.003. Epub 2008 Nov 18.

10.

Targeting of bone morphogenetic protein growth factor complexes to fibrillin.

Sengle G, Charbonneau NL, Ono RN, Sasaki T, Alvarez J, Keene DR, Bächinger HP, Sakai LY.

J Biol Chem. 2008 May 16;283(20):13874-88. doi: 10.1074/jbc.M707820200. Epub 2008 Mar 13.

11.

Abnormal mineral-matrix interactions are a significant contributor to fragility in oim/oim bone.

Miller E, Delos D, Baldini T, Wright TM, Pleshko Camacho N.

Calcif Tissue Int. 2007 Sep;81(3):206-14. Epub 2007 Jul 28.

12.

Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragility.

Jepsen KJ, Hu B, Tommasini SM, Courtland HW, Price C, Terranova CJ, Nadeau JH.

Mamm Genome. 2007 Jul;18(6-7):492-507. Epub 2007 Jun 8.

13.

Marfan syndrome: from molecular pathogenesis to clinical treatment.

Ramirez F, Dietz HC.

Curr Opin Genet Dev. 2007 Jun;17(3):252-8. Epub 2007 Apr 27. Review. Erratum in: Curr Opin Genet Dev. 2007 Aug;17(4):367.

PMID:
17467262
14.

Osteopontin deficiency and aging on nanomechanics of mouse bone.

Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB.

J Biomed Mater Res A. 2007 Oct;83(1):136-44.

PMID:
17390367
15.

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC.

Nat Med. 2007 Feb;13(2):204-10. Epub 2007 Jan 21. Erratum in: Nat Med. 2007 Apr;13(4):511.

16.

FT-IR imaging of native and tissue-engineered bone and cartilage.

Boskey A, Pleshko Camacho N.

Biomaterials. 2007 May;28(15):2465-78. Epub 2006 Dec 18. Review.

17.

Geometric and material contributions to whole bone structural behavior in GDF-7-deficient mice.

Maloul A, Rossmeier K, Mikic B, Pogue V, Battaglia T.

Connect Tissue Res. 2006;47(3):157-62.

PMID:
16753809
18.

Variation in mineral properties in normal and mutant bones and teeth.

Boskey AL, Young MF, Kilts T, Verdelis K.

Cells Tissues Organs. 2005;181(3-4):144-53. Review.

PMID:
16612080
19.

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC.

Science. 2006 Apr 7;312(5770):117-21.

20.

The mechanical phenotype of biglycan-deficient mice is bone- and gender-specific.

Wallace JM, Rajachar RM, Chen XD, Shi S, Allen MR, Bloomfield SA, Les CM, Robey PG, Young MF, Kohn DH.

Bone. 2006 Jul;39(1):106-16. Epub 2006 Mar 9.

PMID:
16527557

Supplemental Content

Support Center